What Hyabak Treats: Main Uses and Benefits

The solution is commonly used in situations involving certain distressing symptoms, such as the temporary relief of burning and irritation due to dryness of the eye. Hyabak is generally used for the supportive management of conditions characterized by tear film instability, including Dry Eye Disease (DED) and keratoconjunctival epithelial disorders. This supports the patient by addressing core symptomatic complaints such as dryness, chronic soreness, and grittiness.

The solution is relevant for easing the impact of symptoms that interfere with daily functioning, such as those that may follow certain procedures or occur due to prolonged visual strain and environmental factors like wind or air conditioning. It is also commonly used to help contact lens wearers to support lubrication. This supportive use contributes to improved comfort during periods of heightened discomfort, reflecting its role in symptomatic relief.

Quick Fact: Relief for Physical Discomfort

Regulatory References

1. Label: LUBRICANT EYE DROPS- sodium hyaluronate solution/ drops - DailyMed

Eligibility Map: Who Can and Cannot Use Hyabak

The following information outlines the official population eligibility and non-eligibility for Hyabak (Sodium Hyaluronate Ophthalmic Solution), based strictly on authoritative governmental regulatory documents.

Eligibility Scope

Resulting Eligibility Structure

Official eligibility statements:

• Use is contraindicated in patients with known hypersensitivity or allergy to the active ingredient or any of the excipients.
• Adults and contact lens wearers are standard, eligible user populations.
• Use in children is considered conditional and not recommended in the absence of sufficient data, requiring professional guidance.
• Use during pregnancy and breastfeeding is considered conditional and not recommended due to the absence of sufficient human data.

Regulatory documents define who can and cannot use the medicine by establishing an absolute exclusion based on ingredient hypersensitivity, while broadly permitting its use in adults. Furthermore, the profile introduces conditional use restrictions for children and pregnant/breastfeeding women, explicitly stating that this limitation is based on the formal finding of absence of sufficient data for these specific population groups.

Interactions with other medicines and products

Official regulatory documentation for Hyabak (Sodium Hyaluronate 0.15% ophthalmic solution) primarily outlines restrictions related to the concurrent use of other topical eye products. This profile is consistent with the product's function as a local ocular lubricant with minimal to no systemic absorption of its active ingredient, Sodium Hyaluronate.

Documented Interaction Patterns

Profile Summary

Regulatory authorities do not list any formal contraindicated combinations with Hyabak. The only constraint is the mandatory 10-minute waiting period when applying it sequentially with other eye drops or ointments. This procedural restriction ensures the lubricant film does not interfere with the proper contact time or subsequent absorption of the other applied medicine.

How Hyabak Works: Mechanism of Action

Physical Ocular Surface Stabilization

The mechanism of action is based on two primary domains. The first involves a physical interaction where sodium hyaluronate, a high-molecular-weight polysaccharide, creates a viscoelastic film that adheres to the ocular surface. This physical layer provides continuous lubrication and increases the stability and residence time of the tear film. This structural enhancement results in reduced friction between the eyelid and the corneal epithelium.

Cellular Osmoprotection and Epithelial Signaling

The second domain is cellular. The solution's hypotonic formulation acts as an osmoprotectant, modulating fluid concentration in hyperosmolar epithelial cells. Additionally, the sodium hyaluronate molecule acts as a ligand for CD44 receptors on corneal cells . Engagement of these receptors initiates intracellular signaling cascades that promote cell migration and re-epithelialization. This process contributes to the maintenance of epithelial integrity on the ocular surface.

Administration Technique

Hyabak is a hypotonic solution intended for use on the surface of the eye or on contact lenses. The solution is delivered via the ABAK system, a multi-dose container designed to provide drops through a filtering membrane that prevents bacterial contamination of the solution without the use of preservatives.

Preparation for Use

Before the first application, ensure the tamper-evident seal on the bottle is intact. Wash hands thoroughly before handling the bottle to maintain hygiene during the application process.

Application Steps

1. Remove the protective cap from the tip of the bottle.
2. Position the head in a slightly tilted back position and look upward.
3. Gently pull the lower eyelid down with one finger to create a small pocket.
4. Hold the bottle vertically above the eye, ensuring the dropper tip does not come into contact with the eye, eyelids, or any other surfaces. This avoids contamination of the remaining solution.
5. Squeeze the bottle gently to release a single drop into the space created by the lower eyelid.
6. Close the eye slowly. Blinking helps distribute the solution evenly across the entire ocular surface.
7. Replace the protective cap immediately after use.

Use with Contact Lenses

Hyabak is compatible with all types of contact lenses. The solution can be applied directly to the eye while wearing lenses. If preferred, a drop can also be applied to the concave part of the lens before it is inserted into the eye.

General Handling and Storage

To ensure the integrity of the solution, the bottle should be stored at room temperature and away from direct light. It is recommended to record the date the bottle was first opened in the space provided on the packaging to monitor the period of use. The bottle should be discarded after the timeframe specified on the product labeling has elapsed from the date of opening.

Recent clinical studies have evaluated the efficacy and safety of Hyabak (a preservative-free ophthalmic solution containing 0.15% sodium hyaluronate) in managing dry eye disease (DED) across various patient groups.

Clinical Efficacy in Diverse Dry Eye Etiologies

Studies involving patients with DED stemming from causes such as contact lens use, intensive screen work, post-surgical effects (e.g., post-refractive surgery or phacoemulsification), and underlying conditions like Sjögren's syndrome and persistent meibomian blepharitis have demonstrated positive outcomes. The use of Hyabak was associated with a marked improvement in both subjective symptoms and objective clinical signs of dry eye. Improvement was assessed using various standard measures:

• Subjective Symptoms: Reduction in discomfort, burning, stinging, and foreign body sensation.
• Objective Signs: Improvement in tear film stability (Tear Break-Up Time or TBUT), reduction in ocular surface damage (corneal and conjunctival staining), and improved tear production (Schirmer's test).

Comparative Performance and Safety

In comparisons with other artificial tear formulations, including those containing preservatives and different lubricating ingredients, Hyabak's efficacy has been found to be comparable, and in some instances, demonstrated greater benefits or a faster onset of action in relieving symptoms and signs. For instance, in a study comparing preservative-free sodium hyaluronate (Hyabak) with a preserved tear substitute following laser vision correction (LASIK), Hyabak was found to be non-inferior in reducing dry eye symptoms and signs.

The formulation's preservative-free nature, delivered via the ABAK® multi-dose system, contributes significantly to its safety profile. Clinical data consistently report that Hyabak is well-tolerated across a wide range of patients, a critical factor for long-term and frequent use, as preservatives common in other products can potentially damage the ocular surface over time.

Common questions about Hyabak (FAQ)

Q: Is Hyabak a prescription-only medicine (POM) or can I buy it over-the-counter (OTC)?

Hyabak is typically regulated as a medical device, not a systemic pharmaceutical drug. Official documentation indicates that this sterile, preservative-free ophthalmic solution is commonly available over-the-counter (OTC) without a prescription for its intended use as an ocular lubricant.

Q: If I use other medicated eye drops, how long do I need to wait before or after using Hyabak?

Official regulatory documents state that you must wait at least 10 minutes between using Hyabak and administering any other eye product, such as medicated drops. This procedural constraint is in place to minimize the chance that the lubricant may affect the application or activity of the subsequent eye drop.

Q: What are the common side effects I should watch out for?

According to the official product information, the most common side effects are mild and temporary. These include transient blurred vision immediately after instillation and mild eye irritation. Due to the possibility of temporary vision changes, regulatory documents advise patients to wait until their vision clears before engaging in activities like driving or operating machinery. A clinically significant, though rare, reaction to watch for is a hypersensitivity or allergic response to one of the components.

How to Store and Dispose of Hyabak?

Official regulatory documents define strict storage and disposal requirements to maintain product quality and safety.

Storage and Handling Constraints

Disposal Instructions

To dispose of the product, discard any remaining solution responsibly after the 6-month in-use period. The bottle should be disposed of as household waste, while the outer carton and the leaflet are typically recyclable according to local municipal guidelines.